Molecular Oncology
Volume 1, Issue 3 , Pages 246-251 , December 2007

The MINDACT trial: The first prospective clinical validation of a genomic tool

  • Fatima Cardoso

      Affiliations

    • Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    • Corresponding Author InformationCorresponding author. Tel.: +32 2 541 30 82; fax: +32 2 538 08 58.
    • ,
  • Martine Piccart-Gebhart

      Affiliations

    • Department of Medical Oncology, Institut Jules Bordet, Brussels, Belgium
    • ,
  • Laura Van’t Veer

      Affiliations

    • Department of Pathology, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • Emiel Rutgers

      Affiliations

    • Department of Surgery, The Netherlands Cancer Institute, Amsterdam, The Netherlands
    • ,
  • on behalf of the TRANSBIG consortium

Received 2 October 2007 ,Revised 11 October 2007 ,Accepted 17 October 2007.

References 

  1. Ach RA, Floore A, Curry B, et al. Robust interlaboratory reproducibility of a gene expression signature measurement consistent with the needs of a new generation of diagnostic tools. BMC Genomics. 2007;8:148
  2. Bogaerts J, Cardoso F, Buyse M, et al. on behalf of the TRANSBIG consortium Prospective evaluation of a gene signature as a new prognostic tool in early stage breast cancer: background and challenges in the design of MINDACT (Microarray In Node negative Disease May Avoid Chemotherapy Trial). Nat. Clin. Pract. Oncol. 2006;3(10):540–551
  3. Bueno de Mesquita JM, van de Vijver MJ, Peterse JL, et al. Feasibility of gene expression profiling in community hospitals; preliminary results of a pilot study in N0 breast cancer patients. Breast Cancer Res. Treat. 2005;94(Suppl. 1):A309;(abstract 309)
  4. Buyse M, Loi S, van't Veer L, et al. on behalf of the TRANSBIG Consortium Validation and clinical utility of a 70-gene prognostic signature for women with node-negative breast cancer. J. Natl. Cancer Inst. 2006;98(17):1183–1192
  5. Cardoso, F., van't Veer, L., Rutgers, E., et al. Clinical application of the 70-gene profile (MammaPrint™): the MINDACT trial. J. Clin. Oncol., in press.
  6. ClinicalTrials.gov.Identifier: NCT00310180. http://www.clinicaltrials.gov.
  7. ClinicalTrials.gov Identifier: NCT00017095. http://www.clinicaltrials.gov.
  8. Desmedt C, Piette F, Loi S, et al. on behalf of the TRANSBIG Consortium Strong time-dependency of the 76-gene prognostic signature for node-negative breast cancer patients in the TRANSBIG multi-centre independent validation series. Clin. Cancer Res. 2007;13(11):3207–3214
  9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717
  10. Foekens JA, Atkins D, Zhang Y, et al. Multicenter validation of a gene expression-based prognostic signature in lymph node-negative primary breast cancer. J. Clin. Oncol. 2006;24:1665–1671
  11. Goldhirsch A, Glick JH, Gelber RD, et al. Meeting highlights: International Consensus Panel on the Treatment of Primary Breast Cancer. J. Clin. Oncol. 2001;19(18):3817–3827
  12. Hu Z, Fan C, Oh DS, et al. The molecular portraits of breast tumors are conserved across microarray platforms. BMC Genomics. 2006;7:96
  13. Mook S, van't veer LJ, Rutgers E, et al. Individualization of therapy using MammaPrint™: from development to the MINDACT trial. Cancer Genomics Proteomics. 2007;4:147–156
  14. Paik S, Shak S, Tang G, et al. A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N. Engl. J. Med. 2004;351(27):2817–2826
  15. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747–752
  16. Ravdin PM, Siminoff LA, Davis GJ, et al. Computer program to assist in making decisions about adjuvant therapy for women with early breast cancer. J. Clin. Oncol. 2001;19(4):980–991
  17. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. U. S. A. 2001;98(19):10869–10874
  18. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in independent gene-expression data sets. Proc. Natl. Acad. Sci. U. S. A. 2003;100:8418–8423
  19. Sotiriou C, Neo SY, McShane LM, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc. Natl. Acad. Sci. U. S. A. 2003;100(18):10393–10398
  20. Sotiriou C, Wirapati P, Loi S, et al. Gene expression profiling in breast cancer: understanding the molecular basis of histologic grade to improve prognosis. J. Natl. Cancer. Inst. 2006;98(4):262–272
  21. van de Vijver MJ, He YD, van't Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N. Engl. J. Med. 2002;347(25):1999–2009
  22. van't Veer LJ, Dai H, van de Vijver MJ, et al. Gene expression profiling predicts clinical outcome of breast cancer. Nature. 2002;415(6871):530–536
  23. Wang Y, Klijn JG, Zhang Y, et al. Gene-expression profiles to predict distant metastasis of lymph node-negative primary breast cancer. Lancet. 2005;365:671–679

PII: S1574-7891(07)00077-4

doi: 10.1016/j.molonc.2007.10.004

Molecular Oncology
Volume 1, Issue 3 , Pages 246-251 , December 2007

Article Tools

* Image Usage & Resolution